United States: WilmerHale Counsels Aquinnah Pharmaceuticals In $10M Investment From Pfizer And AbbVie
Last Updated: May 2 2017

Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in their work to treat Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment, that WilmerHale also handled, made by Takeda Pharmaceuticals in December 2015.

The WilmerHale team counseling Aquinnah Pharmaceuticals included Joshua Fox and Stephanie Singer.

Read Aquinnah Pharmaceuticals' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
By WilmerHale
By Jamie Gorelick, William McLucas, Bruce M. Berman, Danielle Conley, Tania Faransso
Font Size: